Breaking News, Collaborations & Alliances

MedImmune Granted Access to Pfenex Technology

Pfenex, Inc. has entered a three-year strategic collaboration with MedImmune, the global biologics business of AstraZeneca, granting MedImmune non-exclusive access to Pfenex Expression Technology and resources for the development of bioprocesses for thera

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfenex, Inc. has entered a three-year strategic collaboration with MedImmune, the global biologics business of AstraZeneca, granting MedImmune non-exclusive access to Pfenex Expression Technology and resources for the development of bioprocesses for therapeutic proteins and vaccines. Pfenex, Inc. will engineer production strains and develop early production processes for MedImmune’s molecules. MedImmune will have access to the expression platform and process development team in an effort to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters